Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Senator Dr. Rasha Kelej, CEO of Merck Foundation, the philanthropic arm of Merck KGaA Germany, congratulated H.E. Dr. SAMIA ...

Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Mersana Therapeutics only has eyes for Emi-Le. Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% ...

The researchers argue that member states should harmonize policies, offer stronger incentives for drug development and ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Nektar Therapeutics’s NKTR share price has dipped by 5.47%, which has investors questioning if this is right time to buy.

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...